Following Defense Secretary Pete Hegseth's announcement in July that the U.S. military would begin mandatory testosterone screening for personnel, the Pentagon released a clinical guidance document on September 2 outlining the new policy. The next day, the document and an accompanying statement by spokesperson Sean Parnell were removed from public access. The withdrawal was first reported by the news agency Reuters. In a statement provided to Ars Technica, the Pentagon explained that the document, titled "Clinical Guidance for Health and Human Performance Optimization," had been temporarily rescinded on September 3 to allow for updates. The statement emphasized the Department's commitment to addressing hormone deficiencies, protecting the long-term health of service members, and ensuring peak operational performance. The Pentagon also noted that an interim guidance remains in effect and that the final clinical guidance would be issued shortly. However, it declined to provide further details about the updates or the urgency of the revisions. According to Reuters, the withdrawn guidelines proposed that men aged 30 and older undergo a questionnaire that could lead to a blood test for testosterone levels. If necessary, the guidelines suggested testosterone hormone therapy. Women were also to be screened through a questionnaire, which could result in treatment for hormonal imbalances. The policy aimed to ensure that service members maintain optimal physical and mental health to perform their duties effectively. The rapid reversal of the guidance has raised questions about the clarity and stability of the policy. While the Pentagon has not elaborated on the specific changes being made, the initial proposal sparked debate about the role of hormone screening in military health and performance. The final version of the guidance is expected to be released soon, but for now, the policy remains in a provisional state.